For a world without autoimmune diseases

Therapeutic Vaccines and
Active Targeted Immunotherapies

Who we are

CuraVac is a clinical-stage biotechnology company developing Therapeutic Vaccines and Active Targeted Immunotherapies for autoimmune diseases.

With the use of a new revolutionary technique based on complementary peptides, we aim to induce long-term immunity against autoimmune diseases such as Multiple Sclerosis (MS), Myasthenia Gravis (MG), Type 1 diabetes, Graves’ disease, Systemic Lupus Erythematosus (SLE) and Hashimoto’s disease.

CuraVac’s CV-MG is a potential breakthrough in MG treatments and a potential therapeutic revolution for all autoimmune diseases – being the first to possibly bring a long-lasting improvement and a potential cure to patients. 
Autoimmune diseases in the U.S.
0 M
Grave's Disease
0 M
Hashimoto's Disease
0 K
Type 1 Diabetes
0 K
Multiple Sclerosis (MS)
0 K
Systemic Lupus Erythematosus (SLE)
0 K+
Myasthenia Gravis (MG)

The CuraVac team is composed of 3 key people at the center of a collaborative network of the highest quality from the industry and the academic world: Dr. Stéphane Huberty, Professor J. Edwin Blalock and Nicolas Havelange.

Our Independent Advisory Board is composed of key specialists from the industry and the academic world who provide the management team with valuable input in its strategic decision making.

The Myasterix Team
Foundation

CuraVac was founded in 2002 by Dr. Stéphane Huberty, a Belgian medical doctor who suffered from Myasthenia Gravis. Soon after, the company acquired the complementary peptide patent, raised funds and got organized as a management company at the center of a network of collaborations and sub-contracting companies. The original discoverer of the vaccine production technique, Professor J. Edwin Blalock also joined CuraVac as a consultant.

Present day

Following a Clinical Trial Authorization received in November 2015, 24 patients received three injections of the MG therapeutic vaccine in a phase 1B clinical trial that took place at the Antwerp University hospital (UZA) in Belgium. The preliminary results were communicated in May 2017 at the 13th International Conference on Myasthenia Gravis and Related Disorders at the New York Academy of Science. The final results of phase 1B, communicated in June 2018, demonstrated an excellent safety profile and called for a phase 2 efficacy clinical trial. CuraVac is presently preparing a phase 2 efficacy clinical trial with a more potent formulation of the MG Therapeutic Vaccine: CV-MG02.

They didn’t know it was impossible so they did it

— Mark Twain

Wish to ask us about our progress, our platform, share your story or anything else?
You can send us an email at info@curavac.com or simply submit the form here.